

IODINE
CAS # 7553-56-2
ORAL RISK ASSESSMENT DOCUMENT

**NSF International
Ann Arbor, MI
November 2002**

Copyright 2002 NSF International

TABLE OF CONTENTS

1.0 INTRODUCTION	1
2.0 PHYSICAL AND CHEMICAL PROPERTIES.....	3
2.1 Organoleptic Properties	4
3.0 PRODUCTION AND USE.....	4
3.1 Production	4
3.2 Use	5
3.2.1 Disinfection	5
3.2.2 Food and Drug Applications	7
4.0 ANALYTICAL METHODS	7
4.1 Biological Samples	7
4.2 Environmental Samples	7
5.0 SOURCES OF HUMAN AND ENVIRONMENTAL EXPOSURE.....	8
5.1 Food.....	8
5.2 Water	9
5.3 Iodine-containing Pharmaceuticals and Supplements	9
6.0 THYROID PHYSIOLOGY AND IODINE PHARMACOKINETICS IN HUMANS.....	10
6.1 Key Definitions	10
6.2 Thyroid Gland.....	11
6.3 Iodine Metabolism	11
6.3.1 Absorption	12
6.3.2 Distribution	12
6.3.3 Elimination / Excretion	13
6.4 Thyroid Hormone Synthesis	13
6.5 Thyroid Hormone Secretion	14
6.6 Regulation of Thyroid Hormone Synthesis and Secretion	15
6.7 Thyroid Hormone Binding and Transport.....	15
6.8 Thyroid Hormone Functions	16
6.9 Thyroid Pathology	16
6.9.1 Hypothyroidism	16
6.9.2 Hyperthyroidism.....	17
6.9.3 Nontoxic Goiter	17
6.9.4 Thyroid Nodules and Cancer	17
6.9.5 Clinical Assessment of Thyroid Function	18
7.0 EFFECTS ON HUMANS.....	21
7.1 Single-Exposure Studies	21
7.1.1 General Toxicity.....	21
7.1.2 Case Reports	22
7.2 Limited-Exposure Effects	23

7.2.1 Irritation and Sensitization	23
7.2.2 Ocular Exposure	24
7.3 Short-term and Long-term Effects	24
7.3.1 Euthyroid (No Thyroid Dysfunction)	25
7.3.2 Euthyroid (Preexisting Thyroid Dysfunction)	32
7.3.3 Euthyroid (Preexisting Non-thyroid Illness)	33
7.3.4 Euthyroid/Hypothyroid	34
7.3.5 Goiter (Iodine Deficiency)	35
7.3.6 Goiter (Iodine Excess)	36
7.3.7 Hypothyroidism (Iodine Excess)	38
7.3.8 Thyrotoxicosis (Iodine Excess)	40
7.3.9 Thyrotoxicosis (Drug-induced)	41
7.3.10 Iodine and Autoimmune Thyroid Disease	41
7.3.11 Iodine and Thyroid Cancer	43
7.4 Reproductive and Developmental Toxicity	45
7.4.1 Smyth (1999)	45
7.4.2 Pederson et al. (1993)	46
7.4.3 Momotani et al. (1992)	47
7.4.4 Pharoah and Connolly (1991)	47
7.4.5 Thomas et al. (1979)	48
7.4.6 Ayromloo (1971)	48
7.4.7 Carswell et al. (1970)	49
7.5 Immunological and Neurological Effects	49
8.0 EFFECTS ON LABORATORY ANIMALS AND <i>IN VITRO</i> TEST SYSTEMS	49
8.1 Single Exposure Studies	49
8.1.1 Acute Oral Toxicity – Rat (Product Safety Laboratories, 1992a)	49
8.1.2 Acute Inhalation Toxicity – Rat (Product Safety Laboratories, 1993)	50
8.1.3 Acute Dermal Toxicity – Rabbit (Product Safety Laboratories, 1992b)	50
8.2 Limited Exposure Studies	51
8.2.1 Irritation and Sensitization	51
8.2.2 Ocular Effects	52
8.3 Short-term Exposure Bioassays (Rat)	52
8.3.1 Iodine versus Iodide	52
8.3.2 Iodine Intake and Lymphocytic Thyroiditis	55
8.3.3 Iodine Intake and Intrathyroidal Metabolism	56
8.4 Short-term Exposure Bioassays (Lamb, Cattle, and Swine)	57
8.5 Long-term Exposure Bioassay (Rat)	57
8.5.1 Tanaami et al. (1985)	57
8.6 Tumor Promotion Bioassays	58
8.6.1 Kanno et al. (1992)	58
8.6.2 Yamashita et al. (1990)	59
8.7 <i>In Vivo</i> Thyroid Cell Bioassay	60
8.7.1 Krupp and Lee (1988)	60
8.8 <i>In Vitro</i> Thyroid Cell Bioassays	60
8.8.1 Smerdely et al. (1993)	60
8.8.2 Many et al. (1992)	61
8.8.3 Takasu et al. (1985)	61
8.9 Genotoxicity and Related End-Points	62

8.9.1 Mutagenicity Assays	62
8.9.2 Assays of Chromosomal Damage	63
8.9.3 Other Assays of Genetic Damage	64
8.10 Reproductive and Developmental Toxicity	65
8.10.1 Rat Bioassays.....	65
8.10.2 Multiple Mammalian Species Bioassay.....	67
8.10.3 Hen Bioassays.....	69
8.11 Conclusions – Human and Laboratory Animal Responses to Iodine Species	70
9.0 RISK CHARACTERIZATION.....	71
9.1 Hazard Identification	71
9.1.1 Evaluation of Major Non-Cancer Effects and Modes of Action	74
9.1.2 Weight of Evidence Evaluation and Cancer Characterization.....	75
9.1.3 Selection of Key Study and Critical Effect	75
9.1.4 Identification of Susceptible Populations.....	76
9.2 Dose-Response Assessment	78
9.2.1 Carcinogenic Responses to Iodine	78
9.2.2 Non-Carcinogenic Responses to Iodine.....	78
9.3 Exposure Assessment.....	82
9.4 TAC Derivation.....	83
9.5 STEL Derivation	83
10.0 RISK MANAGEMENT.....	84
10.1 SPAC Derivation.....	84
11.0 RISK COMPARISONS AND CONCLUSIONS	84
11.1 Outside Risk Assessments	84
11.2 Disinfection and Toxicological Risk Comparisons.....	87
12.0 REFERENCES	89
12.1 Reference Cited	89
12.2 References Not Cited	102
13.0 APPENDICES.....	105
13.1 Appendix A: Human Iodine Studies	106
14.0 PEER REVIEW HISTORY.....	110
14.1 Oral Risk Assessment Peer Review (October, 2000)	110
14.2 Oral Risk Assessment Peer Review (April 2002)	110

AUTHORS, PEER REVIEWERS, AND ACKNOWLEDGEMENTS

Authors:

NSF Toxicology Services
1.800.NSF.MARK
NSF International
789 Dixboro Road
Ann Arbor, MI 48105

Disclaimer:

The responsibility for the content of this document remains solely with NSF International, and the authors noted above should be contacted with comments or for clarification. Mention of trade names, proprietary products, or specific equipment does not constitute an endorsement by NSF International nor does it imply that other products may not be equally suitable.

Internal NSF Peer Reviewer(s):

Gwendolyn Ball, Ph.D.
Clif McLellan, M.S.
Maryann Sanders, M.S.

External Peer Reviewers:

NSF gratefully acknowledges the efforts of the following experts on the NSF Health Advisory Board in providing peer review. These peer reviewers serve on a voluntary basis, and their opinions do not necessarily represent the opinions of the organizations with which they are affiliated.

Edward Ohanian, Ph.D. (Chairman, NSF Health Advisory Board)
Acting Director, Health and Ecological Criteria Division
Office of Science and Technology/Office of Water
U.S. Environmental Protection Agency

Michael Dourson, Ph.D., DABT (Vice Chairman, NSF Health Advisory Board)
Director
TERA (Toxicology Excellence for Risk Assessment)

David Blakey, D.Phil.
Acting Director, Environmental Health Science
Safe Environments Programme
Health Canada

Randy Deskin, Ph.D., DABT
Director, Toxicology and Product Regulatory Compliance
Cytec Industries, Inc.

Robert Hinderer, Ph.D.
Director of Health, Toxicology and Product Safety
Noveon, Inc.

Jennifer Orme-Zavaleta, M.S.
Associate Director for Science
U.S. Environmental Protection Agency/NHEERL/WED

Adi Pour, Ph.D.
Director, Douglas County Health Department
Omaha, Nebraska

Calvin Willhite, Ph.D.
Department of Toxic Substances Control
State of California

EXECUTIVE SUMMARY

Iodine – Oral Risk Assessment			
PARAMETER	LEVEL	UNITS	CALCULATED FOR:
NOAEL (no-observed-adverse-effect level)	0.03	mg/kg-day	70 kg Adult
Oral RfD (oral reference dose)	0.01	mg/kg-day	
TAC (total allowable concentration)	0.3	mg/L	70 kg Adult
SPAC (single product allowable concentration)	0.1	mg/L	70 kg Adult
STEL (short term exposure level)	0.3	mg/L	10 kg Child
KEY STUDY	Freund et al. 1966. Effect of iodinated water supplies on thyroid function. <i>J Clin Endocrinol Metab</i> 26: 619-624.		
CRITICAL EFFECT	Non-adverse decreases in radioactive iodine uptake (RAI) and increases in serum protein-bound iodine (PBI) by the thyroid.		
UNCERTAINTY FACTORS	<p>Factors applied in calculating the oral RfD:</p> <ul style="list-style-type: none"> 1x for interspecies extrapolation 3x for intraspecies extrapolation 1x for short-term to long-term exposure extrapolation 1x for extrapolation from a LOAEL to a NOAEL 1x for database deficiencies <p>The total uncertainty factor is therefore 3x.</p>		
TOXICITY SUMMARY	<p>Longer-term exposure to excess iodine shows little visible effect on thyroid function in the normal individual due to the highly effective regulatory mechanisms, although excess iodine may induce some degree of thyroid dysfunction in susceptible individuals. Tolerance to iodine is highly variable, with the vast majority of the population able to handle exposure to large quantities of iodine without adverse responses (Dunn, 1998). While individuals with preexisting thyroid conditions, including goiter, Hashimoto's thyroiditis, and cancer, as well as children and aged individuals can be significantly more susceptible to elevated iodine levels, the presence of underlying thyroid disease and/or the age of an individual does not guarantee that the individual will react adversely to elevated iodine concentrations. Likewise, a clinically euthyroid individual may respond atypically to iodine levels at which the general population does not respond.</p>		
CONCLUSIONS	<p>Because the response to excess iodine is highly individual, it is necessary for risk managers to consider the risk versus benefit of adding iodine to the water supply in any given region of the country or world. Consequently, it is suggested that the calculated risk values be used with caution and only after consideration of the environment into which the iodine supplementation is being introduced.</p>		

1.0 INTRODUCTION

This document has been prepared to allow toxicological evaluation of the unregulated contaminant **iodine** in drinking water, as an extractant from one or more drinking water system components tested under NSF/ANSI 61 (2002) or as a contaminant in a drinking water treatment chemical under NSF/ANSI 60 (2002). Iodine has also been evaluated as a drinking water treatment chemical for direct addition to water under NSF/ANSI 60 (2002). Both non-cancer and cancer endpoints have been considered, and risk assessment methodology developed by the U.S. Environmental Protection Agency (U.S. EPA) has been used.

Non-cancer endpoints are evaluated using the reference dose (RfD) approach (Barnes and Dourson, 1988; Dourson, 1994; U.S. EPA/IRIS, 1993), which assumes that there is a threshold for these endpoints that will not be exceeded if appropriate uncertainty factors (Dourson et al., 1996) are applied to the highest dose showing no significant effects. This highest dose is derived from human exposure data when available, but more often is derived from studies in laboratory animals. Either the no-observed-adverse-effect level (NOAEL) taken directly from the dose-response data, or the calculated lower 95% confidence limit on the dose resulting in an estimated 10% increase in response (the LED₁₀ or BMDL from benchmark dose programs) can be used (U.S. EPA, 2001). The lowest-observed-adverse-effect level (LOAEL) can also be used, with an additional uncertainty factor, although the benchmark dose approach is preferred in this case. The RfD is expressed in mg/kg-day. It is defined by the U.S. EPA as “an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime” (Barnes and Dourson, 1988; U.S. EPA/IRIS, 1993; U.S. EPA, 1999a).

NSF uses the RfD to derive three product evaluation criteria for non-cancer endpoints. The total allowable concentration (TAC), generally used to evaluate the results of extraction testing normalized to static at-the-tap conditions, is defined as the RfD multiplied by the 70 kg weight of an average adult assumed to drink 2 liters of water per day. A relative source contribution (RSC), to ensure that the RfD is not exceeded when food and other non-water sources of exposure to the chemical are considered, is also applied in calculating the TAC. The relative source contribution should be data derived, if possible. Alternately, a 20% default contribution for water can be used (U.S. EPA, 1991a). The TAC calculation is then as follows:

$$\text{TAC (mg/L)} = \frac{[\text{RfD (mg/kg-day)} \times 70 \text{ kg}] - [\text{total contribution of other sources (mg/day)}]}{2\text{L/day}}$$

or

$$\text{TAC (mg/L)} = \frac{\text{RfD (mg/kg-day)} \times 70 \text{ kg}}{2\text{L/day}} \times 0.2 \text{ (RSC)}$$

The single product allowable level (SPAC), used for water treatment chemicals and for water contact materials normalized to flowing at-the-tap conditions, is the TAC divided by the estimated total number of sources of the substance in the drinking water treatment and